Kevin A Schulman

List of Publications by Year
in descending order

147	6,613	76196	76769
papers	citations	40 h-index	74 g-index

156	156	156	7685
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ethical and Scientific Implications of the Globalization of Clinical Research. New England Journal of Medicine, 2009, 360, 816-823.	13.9	628
2	Delivering affordable cancer care in high-income countries. Lancet Oncology, The, 2011, 12, 933-980.	5.1	571
3	Patterns of breast carcinoma treatment in older women. Cancer, 2000, 89, 561-573.	2.0	264
4	Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods. , 1997, 6, 243-252.		235
5	Time to Presentation With Acute Myocardial Infarction in the Elderly. Circulation, 2000, 102, 1651-1656.	1.6	225
6	Perceptions of Patients and Physicians Regarding Phase I Cancer Clinical Trials: Implications for Physician-Patient Communication. Journal of Clinical Oncology, 2003, 21, 2589-2596.	0.8	210
7	A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors. New England Journal of Medicine, 2002, 347, 1335-1341.	13.9	190
8	Early Convalescent Plasma for High-Risk Outpatients with Covid-19. New England Journal of Medicine, 2021, 385, 1951-1960.	13.9	177
9	Economic Return of Clinical Trials Performed Under the Pediatric Exclusivity Program. JAMA - Journal of the American Medical Association, 2007, 297, 480.	3.8	148
10	Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. Journal of General Internal Medicine, 2005, 20, 578-583.	1.3	136
11	Beyond Politics â€" Promoting Covid-19 Vaccination in the United States. New England Journal of Medicine, 2021, 384, e23.	13.9	133
12	Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Supportive Care in Cancer, 2007, 15, 869-876.	1.0	130
13	Impact of Quality of Life on Patient Expectations Regarding Phase I Clinical Trials. Journal of Clinical Oncology, 2000, 18, 421-421.	0.8	115
14	Reducing the costs of phase III cardiovascular clinical trials. American Heart Journal, 2005, 149, 482-488.	1.2	114
15	Estimating country-specific cost-effectiveness from multinational clinical trials. , 1998, 7, 481-493.		107
16	The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer, 2003, 98, 166-175.	2.0	101
17	Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions. Medical Care, 2004, 42, 164-175.	1.1	97
18	Randomized Trial of Filgrastim, Sargramostim, or Sequential Sargramostim and Filgrastim After Myelosuppressive Chemotherapy for the Harvesting of Peripheral-Blood Stem Cells. Journal of Clinical Oncology, 2000, 18, 43-43.	0.8	92

#	Article	IF	Citations
19	Decision making and quality of life in the treatment of cancer: a review. Supportive Care in Cancer, 2009, 17, 117-127.	1.0	92
20	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. JACC: Heart Failure, 2014, 2, 159-165.	1.9	91
21	Administrative Costs Associated With Physician Billing and Insurance-Related Activities at an Academic Health Care System. JAMA - Journal of the American Medical Association, 2018, 319, 691.	3.8	91
22	Resource costing for multinational neurologic clinical trials: methods and results. , 1998, 7, 629-638.		85
23	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. American Heart Journal, 2005, 149, 434-443.	1.2	82
24	The Effect of Race on the Referral Process for Invasive Cardiac Procedures. Medical Care Research and Review, 2000, 57, 162-180.	1.0	77
25	Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology, 2005, 42, 1406-1413.	3.6	74
26	Cost-effectiveness of imatinib versus interferon-? plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, 101, 2574-2583.	2.0	72
27	A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Supportive Care in Cancer, 2001, 9, 545-551.	1.0	71
28	Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theoretical Medicine and Bioethics, 2003, 24, 329-344.	0.4	64
29	Assessment of Electronic Health Record Use Between US and Non-US Health Systems. JAMA Internal Medicine, 2021, 181, 251.	2.6	64
30	Can Team-Based Care Improve Patient Satisfaction? A Systematic Review of Randomized Controlled Trials. PLoS ONE, 2014, 9, e100603.	1.1	63
31	Implications of Pharmacogenomics for Drug Development and Clinical Practice. Archives of Internal Medicine, 2005, 165, 2331.	4.3	61
32	Toward estimating the impact of changes in immigrants' insurance eligibility on hospital expenditures for uncompensated care. BMC Health Services Research, 2003, 3, 1.	0.9	60
33	A model for the adoption of ICT by health workers in Africa. International Journal of Medical Informatics, 2012, 81, 773-781.	1.6	58
34	Entry and competition in generic biologics. Managerial and Decision Economics, 2007, 28, 439-451.	1.3	55
35	Consistency of Financial Interest Disclosures in the Biomedical Literature: The Case of Coronary Stents. PLoS ONE, 2008, 3, e2128.	1.1	50
36	A Strategy for Collecting Pharmacoeconomic Data During Phase II/III Clinical Trials. Pharmacoeconomics, 1996, 9, 264-277.	1.7	49

#	Article	IF	Citations
37	The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs. Health Affairs, 2014, 33, 1714-1720.	2.5	49
38	A comparison of scoring weights for the EuroQolï¿½ derived from patients and the general public. Health Economics (United Kingdom), 2001, 10, 27-37.	0.8	48
39	Ethical issues in using ambient intelligence in health-care settings. The Lancet Digital Health, 2021, 3, e115-e123.	5.9	48
40	Results of the Economic Evaluation of the FIRST Study:A Multinational Prospective Economic Evaluation. International Journal of Technology Assessment in Health Care, 1996, 12, 698-713.	0.2	47
41	Economic Evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of) Tj ETQq1 1 0.784314 rgBT /Overl 2010, 3, 374-381.	0.9	46
42	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2004, 148, 122-128.	1.2	44
43	Association Between the Medicare Modernization Act of 2003 and Patient Wait Times and Travel Distance for Chemotherapy. JAMA - Journal of the American Medical Association, 2008, 300, 189.	3.8	44
44	The Effect of Pharmaceutical Benefits Managers: Is It Being Evaluated?. Annals of Internal Medicine, 1996, 124, 906.	2.0	42
45	When Vaccine Apathy, Not Hesitancy, Drives Vaccine Disinterest. JAMA - Journal of the American Medical Association, 2021, 325, 2435.	3.8	40
46	Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. Pharmacoeconomics, 2008, 26, 435-446.	1.7	38
47	Patient Choice of Breast Cancer Treatment. Medical Care, 2002, 40, 1068-1079.	1.1	37
48	Quantifying Parkinsonâ€™s disease motor severity under uncertainty using MDS-UPDRS videos. Medical Image Analysis, 2021, 73, 102179.	7.0	37
49	Barriers to Achieving Economies of Scale in Analysis of EHR Data. Applied Clinical Informatics, 2017, 08, 826-831.	0.8	36
50	Long-term survival estimates for imatinib versus interferon-? plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, 101, 2584-2592.	2.0	35
51	Understanding Frequent Emergency Department Use Among Primary Care Patients. Population Health Management, 2018, 21, 24-31.	0.8	31
52	Relationships Between Sponsors and Investigators in Pharmacoeconomic and Clinical Research. Pharmacoeconomics, 1995, 7, 206-220.	1.7	29
53	Patient Preferences for Features of Health Care Delivery Systems: A Discrete Choice Experiment. Health Services Research, 2016, 51, 704-727.	1.0	29
54	Fueling Innovation In Medical Devices (And Beyond): Venture Capital In Health Care. Health Affairs, 2008, 27, w68-w75.	2.5	28

#	Article	IF	Citations
55	COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIAL. International Journal of Technology Assessment in Health Care, 2003, 19, 396-406.	0.2	27
56	Specialty Pharmaceuticals for Hyperlipidemia â€" Impact on Insurance Premiums. New England Journal of Medicine, 2015, 373, 1591-1593.	13.9	26
57	The COVID-19 Pandemicâ€"An Opportune Time to Update Medical Licensing. JAMA Internal Medicine, 2021, 181, 307.	2.6	26
58	The timing of do-not-resuscitate orders and hospital costs. Journal of General Internal Medicine, 1999, 14, 190-192.	1.3	25
59	Does Reimportation Reduce Price Differences for Prescription Drugs? Lessons from the European Union. Health Services Research, 2008, 43, 1308-1324.	1.0	25
60	Treatment Choices by Seriously Ill Patients. Medical Decision Making, 1998, 18, 84-94.	1.2	24
61	Financing and Distribution of Pharmaceuticals in the United States. JAMA - Journal of the American Medical Association, 2017, 318, 21.	3.8	24
62	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research, 0, 2, 23.	2.0	24
63	Pharmacoeconomics: State of the Art in 1997. Annual Review of Public Health, 1997, 18, 529-548.	7.6	23
64	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal, 2005, 150, 323-329.	1.2	23
65	Personalized medicine and disruptive innovation: Implications for technology assessment. Genetics in Medicine, 2009, 11, 577-581.	1.1	23
66	The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: A policy primer for clinicians. American Heart Journal, 2018, 206, 113-122.	1.2	23
67	An Exploration of Relative Health Stock in Advanced Cancer Patients. Medical Decision Making, 2004, 24, 614-624.	1.2	22
68	Digital Health COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. NAM Perspectives, 2022, 2022, .	1.3	22
69	Treatment of hypertension in patients with comorbidities Results from the study of hypertensive prescribing practices (SHyPP). American Journal of Hypertension, 1999, 12, 333-340.	1.0	21
70	Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices. Journal of General Internal Medicine, 2008, 23, 50-56.	1.3	20
71	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research, 2018, 2, 23.	2.0	20
72	The Implications of â€œMedicare for Allâ€•for US Hospitals. JAMA - Journal of the American Medical Association, 2019, 321, 1661.	3.8	19

#	Article	IF	Citations
73	Evaluation of quality of life for diverse patient populations. Breast Cancer Research and Treatment, 1996, 40, 87-104.	1.1	18
74	Publication or presentation of results from multicenter clinical trials: Evidence from an academic medical center. American Heart Journal, 2007, 153, 674-680.	1.2	18
75	Options to Promote Competitive Generics Markets in the United States. JAMA - Journal of the American Medical Association, 2015, 314, 2129.	3.8	18
76	Extreme Home Makeover â€" The Role of Intensive Home Health Care. New England Journal of Medicine, 2016, 375, 1707-1709.	13.9	18
77	Modeling the Potential Economic Impact of the Medicare Comprehensive Care for Joint Replacement Episode-Based Payment Model. Journal of Arthroplasty, 2017, 32, 3268-3273.e4.	1.5	18
78	Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 113-119.	0.9	17
79	Reassessing ACOs and Health Care Reform. JAMA - Journal of the American Medical Association, 2016, 316, 707.	3.8	17
80	Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. American Heart Journal, 2008, 156, 879-885.	1.2	15
81	A policy approach to the development of molecular diagnostic tests. Nature Biotechnology, 2010, 28, 1157-1159.	9.4	15
82	Associations Between Seattle Heart Failure Model Scores andÂHealth Utilities: Findings From HF-ACTION. Journal of Cardiac Failure, 2013, 19, 311-316.	0.7	15
83	Item Responsiveness of a Rhinitis and Asthma Symptom Score During a Pollen Season. Journal of Asthma, 1999, 36, 459-465.	0.9	14
84	The medicare modernization act and reimbursement for outpatient chemotherapy. Cancer, 2007, 110, 2304-2312.	2.0	14
85	The Evolving Pharmaceutical Benefits Market. JAMA - Journal of the American Medical Association, 2018, 319, 2269.	3.8	14
86	Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?. JAMA - Journal of the American Medical Association, 2021, 326, 383.	3.8	14
87	Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Current Medical Research and Opinion, 2005, 21, 1527-1533.	0.9	13
88	Differences in care-seeking behavior for acute chest pain in the United States and Japan. American Heart Journal, 2004, 147, 630-635.	1.2	12
89	Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia. Pharmacoeconomics, 2006, 24, 479-494.	1.7	12
90	Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. Journal of Cardiac Failure, 2013, 19, 611-620.	0.7	12

#	Article	IF	Citations
91	The No Surprises Act and Informed Financial Consent. New England Journal of Medicine, 2021, 385, 1348-1351.	13.9	12
92	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. Gates Open Research, 0, 2, 23.	2.0	12
93	The relationship between perceived barriers to healthcare and self-rated health. Psychology, Health and Medicine, 2004, 9, 476-482.	1.3	11
94	PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability. JAMA - Journal of the American Medical Association, 2017, 318, 711.	3.8	11
95	Are U.S. Hospitals Still â€œRecession-proofâ€?. New England Journal of Medicine, 2020, 383, e82.	13.9	11
96	A claims data approach to defining an episode of care. Pharmacoepidemiology and Drug Safety, 2001, 10, 417-427.	0.9	10
97	Racial disparities in healthcare and health. Health Services Research, 2022, 57, 218-222.	1.0	10
98	A Health Services Approach for the Evaluation of Innovative Pharmaceutical and Biotechnology Products. Drug Information Journal, 1995, 29, 1405-1414.	0.5	9
99	Medical errors: how the US Government is addressing the problem. Current Controlled Trials in Cardiovascular Medicine, 2000, 1, 35.	1.5	9
100	Impact of disease severity and gastrointestinal side effects on the health state preferences of patients with osteoarthritis. Arthritis and Rheumatism, 2005, 52, 2366-2375.	6.7	9
101	Patterns of breast carcinoma treatment in older women. Cancer, 2000, 89, 561-573.	2.0	9
102	The economics of PCSK-9 inhibitors. American Heart Journal, 2017, 189, 200-201.	1.2	8
103	Novel strategies to support global promotion of COVID-19 vaccination. BMJ Global Health, 2021, 6, e006066.	2.0	8
104	Analytic Considerations in Economic Evaluations of Multinational Cardiovascular Clinical Trials. Value in Health, 2006, 9, 281-291.	0.1	7
105	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. American Heart Journal, 2015, 170, 951-960.	1.2	7
106	Evaluating the quality of antihypertensive drugs in Lagos State, Nigeria. PLoS ONE, 2019, 14, e0211567.	1.1	7
107	Costâ€effectiveness of the oral adsorbent ASTâ€120 versus placebo for chronic kidney disease. Nephrology, 2008, 13, 419-427.	0.7	6
108	Health Care Tax Inversions â€” Robbing Both Peter and Paul. New England Journal of Medicine, 2016, 374, 1005-1007.	13.9	6

#	Article	IF	Citations
109	Comanagement by Hospitalists: Why It Makes Clinical and Fiscal Sense. American Journal of Medicine, 2020, 133, 257-258.	0.6	6
110	The unintended consequences of the 340B safetyâ€net drug discount program. Health Services Research, 2020, 55, 153-156.	1.0	6
111	Reducing administrative costs in US health care: Assessing single payer and its alternatives. Health Services Research, 2021, 56, 615-625.	1.0	6
112	Cost-Effectiveness of Truncated Therapy for Hepatitis C Based on Rapid Virologic Response. Value in Health, 2012, 15, 876-886.	0.1	5
113	Associations Between Seattle Heart Failure Model Scores and Medical Resource Use and Costs: Findings From HF-ACTION. Journal of Cardiac Failure, 2014, 20, 541-547.	0.7	5
114	Trends and determinants of retail prescription drug costs. Health Services Research, 2022, 57, 548-556.	1.0	5
115	Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs. Pharmacoeconomics, 2010, 28, 429-438.	1.7	4
116	Identifying solutions to meet unmet needs of family caregivers using human-centered design. BMC Geriatrics, 2022, 22, 94.	1.1	4
117	Study of Hypertensive Prescribing Practices (SHyPP): A National Survey of Primary Care Physicians. Journal of Clinical Hypertension, 1999, 1, 106-114.	1.0	4
118	Building a Learning Health System: Creating an Analytical Workflow for Evidence Generation to Inform Institutional Clinical Care Guidelines. Applied Clinical Informatics, 2022, 13, 315-321.	0.8	4
119	Association between state-level malpractice environment and clinician electronic health record (EHR) time. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 1069-1077.	2.2	4
120	Assessment of joint review of radiologic studies by a primary care physician and a radiologist. Journal of General Internal Medicine, 1996, 11, 608-612.	1.3	3
121	Health City Cayman Islands and the globalization of health services delivery. American Heart Journal, 2014, 167, 770-774.	1.2	3
122	Workforce Cost Model for Expanding Congenital and Rheumatic Heart Disease Services in Kenya. World Journal for Pediatric & Congenital Heart Surgery, 2019, 10, 321-327.	0.3	3
123	Exploring payments in the US pharmaceutical market from 2011 to 2019: Update on pharmacy benefit manager impact. American Heart Journal, 2020, 227, 107-110.	1.2	3
124	Challenges In Ensuring The Quality Of Generic Medicines. Health Affairs, 2020, 39, 1643-1646.	2.5	3
125	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care, 2020, 43, 2485-2492.	4.3	3
126	Examining Pharmaceutical Benefits in the United Statesâ€"A Framework. JAMA Health Forum, 2020, 1, e200291.	1.0	3

#	Article	IF	Citations
127	Trends in hospital-physician integration in medical oncology. American Journal of Managed Care, 2017, 23, 624-627.	0.8	3
128	Detailed characterization of hospitalized patients infected with the Omicron variant of SARSâ€CoVâ€2. Journal of Internal Medicine, 2022, 292, 385-387.	2.7	3
129	The Development of Standard Economic Datasets for use in the Economic Evaluation of Medicines. Drug Information Journal, 2000, 34, 1273-1291.	0.5	2
130	Understanding Attitudes toward Clinical Research. Journal of Ambulatory Care Management, 2003, 26, 88-90.	0.5	2
131	Exploring Workplace Testing with Real-Time Polymerase Chain Reaction SARS-CoV-2 Testing. Journal of the American Board of Family Medicine, 2022, 35, 96-101.	0.8	2
132	Price and Quality in the Generic Pharmaceutical Market. Circulation, 2022, 145, 1185-1187.	1.6	2
133	Telemedicine: Future Promise for Dialysis Management. Seminars in Dialysis, 2002, 12, S-101-S-103.	0.7	1
134	Improving patients' experiences with cancer treatment. Clinical Therapeutics, 2003, 25, 665-670.	1.1	1
135	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. Drug Information Journal, 2007, 41, 491-499.	0.5	1
136	Shifting toward Defined Contributions â€" Predicting the Effects. New England Journal of Medicine, 2014, 370, 2462-2465.	13.9	1
137	The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents.. Blood, 2004, 104, 234-234.	0.6	1
138	New Medicare Technology Add-On Payment Could Be Used As A Market Support Mechanism To Accelerate Antibiotic Innovation. Health Affairs, 2021, 40, 1926-1934.	2.5	1
139	The Dysfunctional Health Benefits Market and Implications for US Employers and Employees. JAMA - Journal of the American Medical Association, 2022, 327, 323.	3.8	1
140	Regulating manufacturer-affiliated communication in the information age. Clinical Pharmacology and Therapeutics, 1999, 65, 593-597.	2.3	0
141	Commentary: Garson's â€œphysicians, coverage, quality, and cost: the intertwined caduceusâ€• Journal of the American College of Cardiology, 2004, 43, 6-7.	1.2	0
142	Response to Letter Regarding Article, â€œRandomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trialâ€• Circulation, 2009, 120, .	1.6	0
143	End Point Selection in Acute Decompensated Heart Failure Clinical Trials: Economic End Points. Heart Failure Clinics, 2011, 7, 529-537.	1.0	0
144	Petryna, Adriana. 2009. When experiments travel: Clinical trials and the global search for human subjects. Journal of Bioethical Inquiry, 2011, 8, 95-96.	0.9	0

#	Article	IF	Citations
145	The Partners HealthCare Settlement and the Future of Health Care Organizations. Economists' Voice, 2014, 11, .	0.2	0
146	ACI-TIPI Clinical Trial. Annals of Internal Medicine, 1999, 131, 476.	2.0	0
147	Pharmacoeconomics: Economic Evaluation of Pharmaceuticals. , 0, , 629-652.		0